Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Organon Q4 2025 Earnings Call - Flat 2026 Outlook, Debt Reduction Takes Priority After JADA Sale
Organon closed 2025 with $6.2 billion of revenue and about $1.9 billion of adjusted EBITDA, and management is guiding to roughly the same results for 2026. The story is one of stabilization rather tha...
- Full year 2025 revenue was $6.2 billion, with adjusted EBITDA of about $1.9 billion; revenue was down 3% on both reported and ex-FX basis versus 2024.
- Organon is guiding to roughly flat results in 2026: about $6.2 billion of revenue and about $1.9 billion of adjusted EBITDA, pro forma for the JADA System divestiture and with an FX tailwind offsetting the loss of JADA revenue.
- Organon completed the divestiture of the JADA System in January for approximately $390 million in net proceeds, and management intends to apply proceeds to reduce net debt.
- +17 more takeaways
PHINIA Q4 2025 Earnings Call - Guides mid-single-digit 2026 growth with strong cash generation and shareholder returns
PHINIA closed 2025 with a resilient quarter and reiterated a capital-light, cash-first playbook for 2026. Q4 revenue was $889 million, Adjusted EBITDA $116 million, and adjusted EPS $1.18. Management ...
- Q4 2025 revenue $889 million, up 6.7% year over year; excluding FX and SEM contribution, revenue rose ~2.3% in the quarter.
- Adjusted EBITDA for Q4 was $116 million, a 13% margin, with adjusted EPS (ex-nonoperating items) of $1.18 vs. $0.71 a year ago.
- Full-year adjusted revenue ~ $3.5 billion, up ~3% year over year when excluding certain 2024 contract manufacturing; full-year adjusted EBITDA $478 million, essentially flat year over year.
- +12 more takeaways
Himax Technologies Q4 2025 Earnings Call - CPO and WiseEye Positioning Signal 2027 Revenue Levers, while 2026 Starts With a Trough
Himax closed Q4 with modest sequential revenue growth and a profitable quarter, but the call was dominated by a forward-looking storyline. Management paints 2026 as a trough quarter, expecting a rebou...
- Q4 revenue $203.1 million, up 2.0% sequentially, gross margin 30.4% in the quarter, and profit per diluted ADS reported in the call with conflicting figures (call notes both $0.036 and $0.086).
- Full year 2025 revenue $832.2 million, down 8.2% year-over-year; net profit $43.9 million, or $0.25 per diluted ADS, versus $79.8 million in 2024.
- Q4 segment mix: large display driver $21.7 million (10.7% of revenue); small/medium display drivers $139.1 million (68.5%); non-driver products $42.3 million (20.8%).
- +15 more takeaways
Nebius Group Q4 2025 Earnings Call - Capacity Sprint: Contracted Power Tops 2GW, Targeting >3GW and $7B-$9B ARR
Nebius closed 2025 with rapid scale and striking commercial momentum. Q4 revenue was $228 million, ARR exceeded guidance at $1.2 billion, and the core AI cloud business grew at hyperscale speed, with ...
- Q4 revenue $228 million, up 547% year over year and 56% quarter over quarter, with the company in mid-range of guidance.
- Annualized run rate revenue (ARR) for the core AI cloud hit $1.2 billion at year-end, above the high end of prior guidance.
- Core AI cloud revenue grew 830% year over year and 63% quarter over quarter, driving improved operating leverage.
- +15 more takeaways
Karyopharm Therapeutics Q4 2025 Earnings Call - Myelofibrosis Phase 3 SENTRI Readout in March Could Reframe Franchise
Karyopharm enters 2026 hinged on two late stage readouts, with the SENTRI phase 3 myelofibrosis top line expected in March and EXPORT-EC042 endometrial cancer data due mid-2026. Management argues seli...
- SENTRI phase 3 myelofibrosis top-line data expected in March 2026, company views this as the primary near-term value driver.
- EXPORT-EC042 phase 3 in P53 wild-type endometrial cancer remains on track for mid-2026 top-line data, with mandated dual antiemetics and a lower 60 mg selinexor dose versus prior trials.
- Selinexor 60 mg once weekly was selected for SENTRI based on phase 1 PK, efficacy and safety data, with company arguing 60 mg maximizes efficacy while remaining manageable.
- +12 more takeaways
West Pharmaceutical Services Q4 2025 Earnings Call - HVP components drive momentum, 2026 guided to 5%-7% organic growth
West closed 2025 with a clean set of beats and a clear thesis: higher-value product components are doing the heavy lifting. Q4 results outpaced expectations, driven by a 15% organic surge in HVP compo...
- Q4 revenue $805 million, reported growth 7.5%, organic growth 3.3%, beating management expectations.
- Full year 2025 net sales surpassed $3.0 billion with year-over-year organic growth of over 4%.
- HVP components were the standout: $390 million revenue in Q4, organic growth of 15.1%, and the primary driver of margin expansion.
- +12 more takeaways
Manulife Financial Corporation Q4 2025 Earnings Call - Record core earnings driven by double-digit new business CSM growth despite $9.5B GWAM outflows
Manulife closed 2025 with record core earnings, powered by double-digit new business CSM growth across insurance segments and strong performance in Asia and Global WAM, even as the wealth arm recorded...
- Manulife reported record core earnings for 2025, with core EPS up 8% for the year and Q4 core EPS up 9% year over year.
- New business CSM growth exceeded 20% in each insurance segment in 2025, and Manulife recorded its sixth consecutive quarter of >20% new business CSM growth.
- Global WAM posted elevated net outflows of $9.5 billion in Q4, driven by large U.S. retirement plan redemptions and higher participant withdrawals; gross flows rose 15% to $50 billion.
- +13 more takeaways
Lincoln Financial Q4 2025 Earnings Call - Capital rebuilt, annuities shift to spread-based mix to boost free cash flow
Lincoln closed 2025 with clear progress on the three priorities it laid out in 2023: a stronger capital foundation, an optimized operating model, and a shift toward more predictable, capital-efficient...
- Q4 adjusted operating income available to common stockholders was $434 million, or $2.21 per diluted share; full-year adjusted operating income exceeded $1.5 billion, up 23% vs 2024.
- Q4 adjusted operating income rose 31% year-over-year; this was the sixth consecutive quarter of year-over-year adjusted operating earnings growth.
- Free cash flow conversion improved to 45% in 2025, up from 35% in 2023, showing better ability to turn earnings into distributable cash.
- +14 more takeaways
Birkenstock First Quarter Fiscal 2026 Earnings Call - Strong Demand, FX and Tariffs Cut Reported Growth and Margins
Birkenstock posted a robust quarter, with revenue of EUR 402 million, up 18% in constant currency but only 11% reported as a result of a heavy FX headwind. Demand and brand momentum remain strong acro...
- Revenue EUR 402 million in Q1 fiscal 2026, up 18% in constant currency, 11% on a reported basis due to FX effects.
- FX created a 670 basis point headwind to revenue growth in Q1, with Q2 expected to face roughly 700 basis points of FX drag at current rates.
- B2B grew 24% in constant currency in Q1, DTC grew 12% in constant currency; B2B outperformance continued during holiday season.
- +17 more takeaways
Agios Pharmaceuticals Q4 2025 Earnings Call - ACTIVASE U.S. launch underway with 44 scripts in first five weeks and a 10-12 week conversion lag
Agios closed 2025 with a launch under its belt, $1.2 billion of cash, and a pipeline full of near-term catalysts. ACTIVASE received FDA approval in December and the U.S. launch is live, with 44 prescr...
- ACTIVASE approved by the FDA for alpha and beta thalassemia in December 2025; U.S. launch is underway.
- Management reported 44 prescriptions written by REMS-certified physicians in the first five weeks of the U.S. ACTIVASE launch, a strong early signal of demand.
- Average conversion from prescription to treatment initiation is expected to be 10-12 weeks, driven mainly by insurance prior authorization and a required baseline liver test.
- +16 more takeaways